News

UCSF staffers distribute t-shirts at the campus launch event for UCSF: The Campaign in 2017. From left to right: Toshonna Ross, Peggy Huey, Krista Dow and Dresden Joswig. Photo by Elisabeth Fall In the year since announcing an ambitious, $5 billion fundraising campaign, UC San Francisco has seen

Black men in the United States are known to suffer disproportionately from prostate cancer. Now, a new study investigating prostate cancer deaths by race has found that African American men have twice the chance of dying from low-risk prostate cancer than men of other racial and ethnic groups, even

Precision medicine, immunotherapy, and population health led the news at the UCSF Helen Diller Family Comprehensive Cancer Center in 2018. Whether through expediting drug discovery, tailoring genomic sequencing, or expanding palliative care, our UCSF cancer community remained committed to improving

UC San Francisco scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies. In the process, they devised a new two-pronged approach that yields an effective treatment for these cancers in the laboratory and holds tremendous promise for

Hani Sbitany, MD, a plastic and reconstructive surgeon at UCSF Health, performs a breast reconstruction surgery. Sbitany is one of a few surgeons using a procedure that is less invasive and has a less painful recovery. Photo by Susan Merrell For nearly four decades, the main option for breast

The goal of the Small Molecule Discovery Core (SMD) is to help the Cancer Center and other investigators initiate drug discovery and chemical biology projects for their most innovative and exciting new targets. Faculty co-directors Adam Renslo, PhD and Michelle Arkin, PhD, both of UCSF’s

Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system’s cancer-fighting abilities, scientists are becoming expert at manipulating a patient’s own immune cells, turning them into cancer-killing armies. But